- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01712009
NOLAN: Naproxen or Loratadine and Neulasta (NOLAN)
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, the investigational products are naproxen, a non-steroidal antiinflammatory drug (NSAID), and loratadine, an anti-histamine. Both agents are being investigated as prophylactic medications to reduce the incidence and/or severity of bone pain in breast cancer patients receiving adjuvant or neoadjuvant myelosuppressive chemotherapy and pegfilgrastim prophylaxis.
Pegfilgrastim treatment is used to stimulate bone marrow to produce more neutrophils to help fight infections in patients undergoing chemotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Muscle Shoals, Alabama, United States, 35661
- Research Site
-
-
California
-
Anaheim, California, United States, 92801
- Research Site
-
Fullerton, California, United States, 92835
- Research Site
-
Santa Maria, California, United States, 93454
- Research Site
-
Santa Rosa, California, United States, 95403
- Research Site
-
Torrance, California, United States, 90501
- Research Site
-
Whittier, California, United States, 90603
- Research Site
-
-
Colorado
-
Denver, Colorado, United States, 80210
- Research Site
-
Golden, Colorado, United States, 80401
- Research Site
-
Littleton, Colorado, United States, 80122
- Research Site
-
-
Connecticut
-
Norwich, Connecticut, United States, 06360
- Research Site
-
Stamford, Connecticut, United States, 06902
- Research Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33426
- Research Site
-
Daytona Beach, Florida, United States, 32114
- Research Site
-
Daytona Beach, Florida, United States, 32117
- Research Site
-
Fort Lauderdale, Florida, United States, 33308
- Research Site
-
Lakeland, Florida, United States, 33805
- Research Site
-
New Port Richey, Florida, United States, 34652
- Research Site
-
Plantation, Florida, United States, 33324
- Research Site
-
Stuart, Florida, United States, 34994
- Research Site
-
-
Georgia
-
Augusta, Georgia, United States, 30901
- Research Site
-
Thomasville, Georgia, United States, 31792
- Research Site
-
-
Illinois
-
Elmhurst, Illinois, United States, 60126
- Research Site
-
Gurnee, Illinois, United States, 60031
- Research Site
-
Mount Vernon, Illinois, United States, 62864
- Research Site
-
Skokie, Illinois, United States, 60076
- Research Site
-
Urbana, Illinois, United States, 61801
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46237
- Research Site
-
South Bend, Indiana, United States, 46601
- Research Site
-
-
Iowa
-
Sioux City, Iowa, United States, 51101
- Research Site
-
Waterloo, Iowa, United States, 50702
- Research Site
-
-
Kansas
-
Hutchinson, Kansas, United States, 67502
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Research Site
-
Louisville, Kentucky, United States, 40202
- Research Site
-
Mount Sterling, Kentucky, United States, 40353
- Research Site
-
Paducah, Kentucky, United States, 42003
- Research Site
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- Research Site
-
Lafayette, Louisiana, United States, 70503
- Research Site
-
Marrero, Louisiana, United States, 70072
- Research Site
-
Shreveport, Louisiana, United States, 71103
- Research Site
-
-
Maryland
-
Cumberland, Maryland, United States, 21502
- Research Site
-
Randallstown, Maryland, United States, 21133
- Research Site
-
Rockville, Maryland, United States, 20850
- Research Site
-
Westminster, Maryland, United States, 21157
- Research Site
-
-
Massachusetts
-
Lowell, Massachusetts, United States, 01854
- Research Site
-
-
Michigan
-
Battle Creek, Michigan, United States, 49017
- Research Site
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- Research Site
-
Saint Cloud, Minnesota, United States, 56303
- Research Site
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- Research Site
-
-
Missouri
-
Jefferson City, Missouri, United States, 65101
- Research Site
-
Kansas City, Missouri, United States, 64132
- Research Site
-
Saint Joseph, Missouri, United States, 64507
- Research Site
-
Saint Louis, Missouri, United States, 63136
- Research Site
-
-
Montana
-
Billings, Montana, United States, 59101
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68106
- Research Site
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03060
- Research Site
-
-
New Jersey
-
Denville, New Jersey, United States, 07834
- Research Site
-
-
New York
-
East Syracuse, New York, United States, 13057
- Research Site
-
Johnson City, New York, United States, 13790
- Research Site
-
-
North Carolina
-
Gastonia, North Carolina, United States, 28054
- Research Site
-
Hickory, North Carolina, United States, 28602
- Research Site
-
Pinehurst, North Carolina, United States, 28374
- Research Site
-
-
Ohio
-
Massillon, Ohio, United States, 44646
- Research Site
-
Zanesville, Ohio, United States, 43701
- Research Site
-
-
Oregon
-
Bend, Oregon, United States, 97701
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Research Site
-
Langhorne, Pennsylvania, United States, 19047
- Research Site
-
-
South Carolina
-
Florence, South Carolina, United States, 29506
- Research Site
-
-
South Dakota
-
Watertown, South Dakota, United States, 57201
- Research Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Research Site
-
Chattanooga, Tennessee, United States, 37421
- Research Site
-
-
Texas
-
Corpus Christi, Texas, United States, 78412
- Research Site
-
Corpus Christi, Texas, United States, 78404
- Research Site
-
Plano, Texas, United States, 75093
- Research Site
-
-
Utah
-
Ogden, Utah, United States, 84403
- Research Site
-
-
Virginia
-
Chesapeake, Virginia, United States, 23320
- Research Site
-
-
Washington
-
Spokane, Washington, United States, 99208
- Research Site
-
-
West Virginia
-
Huntington, West Virginia, United States, 25701
- Research Site
-
-
Wisconsin
-
Janesville, Wisconsin, United States, 53548
- Research Site
-
Madison, Wisconsin, United States, 53792
- Research Site
-
Racine, Wisconsin, United States, 53405
- Research Site
-
Wauwatosa, Wisconsin, United States, 53226
- Research Site
-
Weston, Wisconsin, United States, 54476
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Age 18 years or over
- Eastern cooperative oncology group (ECOG) performance status 0-2
- Female with newly diagnosed, not previously treated with chemotherapy, stage I-III breast cancer
- Medically eligible to safely receive adjuvant or neoadjuvant chemotherapy, pegfilgrastim, naproxen and loratadine as determined by the investigator
- Creatinine ≤ 1.5 X upper limit of normal (ULN)
- Planning to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy
- Planning to receive prophylaxis with pegfilgrastim starting in the first cycle and continuing throughout each chemotherapy cycle of the treatment period
- Subject has provided informed consent
Exclusion Criteria
History of other malignancy within the past 5 years, with the following exceptions:
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Planning to receive weekly chemotherapy
- Ongoing chronic pain, or other painful conditions requiring treatment (including immediate post-operative treatment of surgical or procedural-associated pain) as determined by the investigator
- Chronic oral steroid use. Premedication related to the administration of chemotherapy, and use of anti-emetics is allowed, per usual clinical practice
Chronic use of oral non-steroidal anti-inflammatory drug (NSAIDs) or oral antihistamines outside of those dictated by the randomization groups outlined in the protocol, with the following exception:
- Chronic oral aspirin use for cardiovascular-related indications
- Prior chemotherapy treatment for cancer within 5 years of current breast cancer diagnosis
- Prior use of granulocyte colony stimulating factor (G-CSF)
- History of clinically significant gastrointestinal (GI) bleeding, history of GI ulcers or active GI bleeding within 6 months prior to randomization
- History of clinically significant bleeding disorders, thromboembolism within 6 months prior to randomization
- Currently enrolled in, or less than 30 days since ending, another clinical trial which includes language directing G-CSF (filgrastim, pegfilgrastim, other) or granulocyte-macrophage colony-stimulating factor (GM-CSF) (sargramostim) use
- Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes a blinded treatment or blinded treatment arm (whether or not the subject is randomized to the blinded arm)
- Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes the use of any agent not currently considered to be standard therapy for the adjuvant or neoadjuvant treatment of stage I-III breast cancer based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer
- Currently enrolled in, or less than 30 days since ending, any pain intervention study
- Female subjects who are pregnant or lactating or of reproductive potential not willing to employ an effective method of birth control during treatment and for 17 days after discontinuing study treatment
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prophylactic naproxen
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
|
Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy.
Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Other Names:
The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
|
Experimental: Prophylactic loratadine
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
|
Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy.
Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Other Names:
The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
|
Other: No prophylactic treatment
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
|
Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy.
Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Other Names:
The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Bone Pain (All Grades) in Cycle 1
Time Frame: Cycle 1 (approximately 4 weeks, depending on the chemotherapy dosing interval)
|
Bone pain data were captured as part of standard adverse event (AE) reporting.
|
Cycle 1 (approximately 4 weeks, depending on the chemotherapy dosing interval)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Bone Pain (All Grades) by Cycle (2-4) and Across Cycles
Time Frame: Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
|
Bone pain data were captured as part of standard adverse event (AE) reporting.
|
Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
|
Percentage of Participants With Severe Bone Pain by Cycle and Across Cycles
Time Frame: Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
|
Bone pain data were captured as part of standard adverse event reporting.
Severe bone pain is defined as grade 3 or 4 according to common terminology criteria for adverse events (CTCAE) version 3 grading criteria: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening or disabling.
|
Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
|
Mean Patient-reported Bone Pain by Cycle and Across Cycles
Time Frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection.
The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale.
Mean patient-reported bone pain values are the average of each participant's bone pain values across survey days 1-5 within each cycle.
Across all cycles the mean is the average of each patient-reported bone pain value across all survey days 1-5 and across all cycles.
An analysis of variance (ANOVA) model with treatment as explanatory term was used.
|
Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Maximum Patient-reported Bone Pain by Cycle and Across Cycles
Time Frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection.
The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale.
Maximum patient-reported bone pain is the maximum of each participant's bone pain values across survey Days 1-5 within each cycle.
Across all cycles the maximum is the maximum of each patient-reported bone pain value across all survey days 1-5 and across all cycles.
An ANOVA model with treatment as explanatory term was used.
|
Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Area Under the Curve (AUC) for Patient-reported Bone Pain
Time Frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Patient-reported bone pain AUC was calculated using the trapezoidal rule with bone pain scores from day 1 to 5 for each cycle.
The AUC across cycles is the average of AUCs across the cycle.
|
Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
|
Number of Participants With Adverse Events (AEs)
Time Frame: From first dose of investigational product (IP, naproxen or loratidine) or first dose of pegfilgrastim (Peg), whichever occurred first, until 30 days after last dose, up to 24 weeks.
|
Severity was graded using CTCAE version 3. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal; • life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • congenital anomaly/birth defect; • other medically important serious event. The investigator assessed each adverse event for relatedness to investigational product(s) or other protocol-required therapies. |
From first dose of investigational product (IP, naproxen or loratidine) or first dose of pegfilgrastim (Peg), whichever occurred first, until 30 days after last dose, up to 24 weeks.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Dermatologic Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Gout Suppressants
- Histamine H1 Antagonists, Non-Sedating
- Naproxen
- Loratadine
Other Study ID Numbers
- 20110147
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Pain in Stage I - III Breast Cancer
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage 0United States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Agency for Healthcare Research and Quality...Active, not recruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage 0United States, Guam, Puerto Rico
-
University Health Network, TorontoRecruitingLymphoma | Lymphoproliferative Disorders | Breast Cancer Stage I | Breast Cancer Stage II | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Breast Cancer Stage III | Colorectal Cancer Stage I | Head and Neck Cancer Stage III | Breast Cancer, Stage 0 | Head and Neck Cancer Stage I | Head and Neck Cancer...Canada
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingGynecologic Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Gynecologic Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer | Stage II Colorectal Cancer | Stage I Gynecologic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Stage I Breast Cancer | Peripheral Neuropathy | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III...United States
-
Thompson Cancer Survival CenterRecruitingBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
-
Dana-Farber Cancer InstituteCURE FoundationCompletedBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage III Breast CancerUnited States
-
University of TorontoCompletedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIICanada
Clinical Trials on Loratadine
-
SandozCompleted
-
BayerCompletedHistamine H1 Antagonists, Non-SedatingGermany
-
Xian-Janssen Pharmaceutical Ltd.Completed
-
Xian-Janssen Pharmaceutical Ltd.Completed
-
Merck Sharp & Dohme LLCCompletedRhinitis, Allergic, Perennial | Rhinitis, Allergic, Seasonal | Pruritus | Urticaria
-
Ranbaxy Laboratories LimitedCompleted
-
Thammasat UniversityCompletedQuality of Life | Allergic Rhinitis | Adverse Drug EventThailand
-
BayerCompletedAllergic RhinitisUnited States
-
Merck Sharp & Dohme LLCCompletedPerennial Allergic Rhinitis